Mr. Ramzi Benamar reports

BELLUS HEALTH INC. ANNOUNCES VOTING RESULTS FROM SPECIAL MEETING OF SHAREHOLDERS

Bellus Health Inc. has released the positive outcome of the Bellus shareholders vote at this morning's special meeting of the shareholders held in-person, approving the previously announced statutory plan of arrangement under Section 192 of the Canada Business Corporations Act pursuant to which 14934792 Canada Inc. (the purchaser), a corporation existing under the laws of Canada and a wholly owned subsidiary of GSK PLC, will acquire, for a purchase price of $14.75 (U.S.) in cash per share, all of the issued and outstanding common shares of Bellus.

A total of 89,309,640 votes, or 99.99 per cent of the votes cast at the special meeting by shareholders present or represented by proxy were cast in favour of the special resolution approving the arrangement (82,218,148 votes, or 99.99 per cent of the votes cast in favour of the arrangement resolution, excluding shares required to be excluded pursuant to Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions). The arrangement resolution was required to be passed by (i) at least two-thirds of the votes cast at the special meeting by the shareholders present or represented by proxy and entitled to vote at the special meeting; and (ii) a simple majority of the votes cast at the special meeting by the shareholders present or represented by proxy and entitled to vote at the special meeting, excluding for this purpose any person required to be excluded pursuant to Multilateral Instrument 61-101 -- Protection of Minority Security Holders in Special Transactions. Details of the voting results will be filed under the company's profile on the SEC website and on SEDAR.

Bellus will present its application for a final order to the Superior Court of Quebec on June 22, 2023. Subject to the court's approval, all closing conditions have currently been met, other than customary closing conditions, and closing is currently expected to occur on or about the end of the second quarter of 2023.

About Bellus Health Inc.

Bellus is a clinical-stage biopharmaceutical company working to better the lives of patients suffering from persistent cough, starting with the development of camlipixant (BLU-5937) for the treatment of refractory chronic cough (RCC). Camlipixant, the company's lead asset, is an investigational P2X3 receptor antagonist for the treatment of RCC, which is currently being evaluated in the Calm phase 3 clinical program. With no approved treatments in the United States, camlipixant has the potential to be a breakthrough in the RCC treatment landscape.

We seek Safe Harbor.